Dysregulation of novel catecholamine-regulated protein 40 (CRP40) in Parkinson's disease patients

Authors

  • Jovana Lubarda PhDc,

    1. Department of Psychiatry and Behavioral Neurosciences, McMaster University, Hamilton, Ontario, Canada
    Search for more papers by this author
    • The first two authors contributed equally to this study.

  • Sarah E. Groleau PhDc,

    1. Department of Psychiatry and Behavioral Neurosciences, McMaster University, Hamilton, Ontario, Canada
    Search for more papers by this author
    • The first two authors contributed equally to this study.

  • Nancy Thomas MSc,

    1. Department of Psychiatry and Behavioral Neurosciences, McMaster University, Hamilton, Ontario, Canada
    Search for more papers by this author
  • Mark A. Ferro PhD,

    1. Department of Psychiatry and Behavioral Neurosciences, McMaster University, Hamilton, Ontario, Canada
    Search for more papers by this author
  • Ram K. Mishra PhD,

    1. Department of Psychiatry and Behavioral Neurosciences, McMaster University, Hamilton, Ontario, Canada
    Search for more papers by this author
  • Joseph P. Gabriele PhD

    Corresponding author
    1. Department of Psychiatry and Behavioral Neurosciences, McMaster University, Hamilton, Ontario, Canada
    • Correspondence to: Dr. J. P. Gabriele, McMaster University, 1200 Main Street West, HSC 4N81, Hamilton, Ontario, Canada L8N 3Z5; gabriejp@mcmaster.ca

    Search for more papers by this author

  • Funding agencies: This work was funded by the Quebec Consortium for Drug Discovery and by the Canadian Institute of Health Research.

  • Relevant conflicts of interest/financial disclosures: Joseph P. Gabriele and Ram K. Mishra jointly hold a patent on Mortalin and its alternative gene product, CRP40.

  • Full financial disclosures and author roles may be found in the online version of this article.

No abstract is available for this article.

Ancillary